←
Alec Nielsen1,484 posts
Alec Nielsen avatar

Alec Nielsen

@alectricity

Multicellular in Boston, Co-founder & CEO @AsimovBio

◷ Joined April 2009▧ 30 Photos and videos
Niko McCarty. avatar
⟳ Alec Nielsen retweeted
Niko McCarty.@NikoMcCarty·Nov 14

I recently learned that the original genetic toggle switch, one of the first synthetic gene circuits ever made, used perhaps the worst possible design. For context: In 2000, two papers appeared back-to-back in Nature: the repressilator and the toggle switch. Both described a synthetic gene circuit and, together, they helped launch the field of synthetic biology. The toggle switch was the simpler design; it had only two genes, one encoding LacI and the other TetR. Each repressed the other, creating two stable states. If you add a small molecule, called an inducer, you could switch cells between those two states. (Really useful! It meant scientists could "program" cells and then switch those cells between different states or behaviors using small molecules.) The researchers built this toggle switch by placing the two promoters next to each other, with transcription pointing outward, like this: ← Gene A | Gene B → This was sensible, because RNA polymerase sometimes blows past the terminator at the end of a gene, thus transcribing into the next gene, too. So their concern was that putting the two genes facing the same direction could cause transcriptional crosstalk. This is why they pointed them away from each other. And the circuit worked OK. Five of six versions they built were bistable, but the switching was extremely slow. It would take 30 minutes to switch to, say, the LacI state, but then multiple hours to coax cells back into the TetR state! So in 2017, Enoch Yeung et al. rebuilt the circuit in three different orientations: divergent (← →, the original), convergent (→ ←), and tandem (→ →). And the original design was the worst one! So much so that increasing the inducer concentration 200-fold only increased gene expression by ~2.7-fold. With the convergent design, on the other hand, an 8x increase in inducer caused a 120-fold increase in expression, meaning it had much faster switching. So what was happening? Well, the original paper was correct about transcriptional bleed-through, but they ignored DNA supercoiling. As RNA polymerase moves along DNA, it overwinds DNA ahead of itself and underwinds DNA behind it. This basically inhibits transcription at nearby promoters, meaning that the original paper had used a design in which, when they added inducer, they were unknowingly repressing both genes via physical changes in the DNA. It's interesting to think about how this gene circuit might not have worked at all; they're lucky, in a way, that it did. Itt also shows how complicated gene circuit design is. You have to think about terminator read-through, promoter strength, DNA supercoiling, and all sorts of interactions; both chemical and physical. Textbooks tend to draw genes as simple arrows in regulatory diagrams, but they're physical objects on a piece of DNA, and require a lot of "know-how" to design well.

Post attachment
Patrick Collison avatar
⟳ Alec Nielsen retweeted
Patrick Collison@patrickc·Nov 8

Two things I’ve been thinking about regarding AI: • People often highlight the risks involved in AI, which are surely very real. I’m struck, however, by how hard it is to understand the contours of the positive scenario. There are easy-to-perceive and frequently invoked elements of a positive vision — more diseases cured, more material abundance, etc. — which sound great, but these are by themselves just ingredients. I’m curious what the larger equilibrium is supposed to look like. Do people work? If so, why? What is their marginal contribution? If not, how are resources allocated? What is scarce? What is the ratio between humans and AIs? Are humans in control, whatever that means? One sometimes hears the Culture novels invoked as one scenario, but I’m not sure they depict a desirable outcome. (AI runs everything and humans compete in games? Iain Banks himself said that the humans in the Culture are “somewhere between passengers, pets and parasites.”) There is Richard Brautigan’s famous poem, but do we want to be “returned to our mammal brothers and sisters”? (Isn’t that rewinding Genesis?) We could say that it was hard to imagine the world of 1900 from the vantage point of 1700, and that’s assuredly true. But nobody in 1700 was trying to recast humanity itself within a couple of years — things necessarily unfolded slowly and by increments, and therefore with the possibility for error correction. Given how rapid the rate of progress in AI may be, it feels strange for the upside case to be so opaque. • There is increasing discussion of whether AIs are conscious or how we would know whether they are, with conclusions there often assumed to be relevant to matters of moral worth. At first blush, this seems a rather arcane, benign, or even absurd issue. (Remember the response to Blake Lemoine’s fears.) Setting aside the terms of the debate itself, or the relevant demarcation criteria, it seems to me a quite high-stakes question, for an affirmative answer — that is, granting moral worth to AIs — would presumably mean that the aggregate worth of AIs would soon outweigh that of humans in any utilitarian calculus. The AIs will be exceptionally wise and intelligent, and vastly more numerous (especially once one considers the imminent future and the AIs not yet born). As such, even epsilon of moral worth will multiply to a lot once one considers the quadrillions that could soon exist. (This is effectively a distributed version of the Nozick’s utility monster.) If this conclusion is unpalatable, I think one of three propositions needs to be rejected: the premise AIs can have moral worth; utilitarianism itself; or the belief that there is even a possibility that they will be far more numerous than humans. With both of these matters (contours of future society; AI moral worth), there is the possibility of dramatic change. Today, people argue about datacenters. I’m curious how popular support for AI will evolve as more people come to understand these medium-term questions and the relevant stakes. What is the vision for AI that most people would be excited about?

Niko McCarty. avatar
⟳ Alec Nielsen retweeted
Niko McCarty.@NikoMcCarty·Oct 29

The new goal at @AsimovPress is to publish exceptional, technical, long-form reporting on biotechnology; the types of stories that no outlet is doing. We are allocating most of our budget toward paying great journalists and also artists who can bring these stories to life. The long-term aim is to win a Pulitzer for biotechnology reporting. This also means we'll be publishing less often, because these stories can take 3-6 months to produce. We'll publish non-reported essays on occasion, but only if they have a thesis that is super compelling and, ideally, could *only* be written by a particular person. (e.g. We have a piece coming up about lead testing, written by a person who is developing those kits.) Please email editors@asimov.com if you have a big story that you are itching to write; especially if other outlets aren't willing to give you the time or funds to do it properly.

Molly Gibson avatar
⟳ Alec Nielsen retweeted
Molly Gibson@gibsmk·Oct 29

It’s interesting to think about what changes in the “pipeline-in-a-person” era. When one scientist + AI can run multiple drug programs, differentiated platform capabilities become way more valuable. More, smaller asset companies = more customers. And now with AI, differentiated platforms should also be able to scale to support enough customers to capture significant platform value. It used to be that the only way to do build valuable platform companies was to own the pipeline internally. Hopefully that’s not the case anymore. It's a great time to be long bio platforms.

Ankit Gupta avatar
⟳ Alec Nielsen retweeted
Ankit Gupta@agupta·Oct 28

Cambridge has always been the best place in the world to be an academic researcher. These days, a lot of cutting edge research also happens in industry, and Cambridge is the home to many amazing research startups, spanning AI research, robotics, biotech, defense, and industrials. We'd love for these two worlds to meet eachother, so we're bringing YC Paper Club to Cambridge! if you're a researcher in industry or academia, request a spot below.

YC Paper Club is coming to Cambridge, MA! YCPC brings together people from academia and industry to discuss the latest research. Our inaugural Cambridge event on November 18 will explore the state of the art in robot learning and control. If you’re a student or faculty at a local university, or a researcher in industry interested in staying up to date with the latest literature, request a spot: events.ycombinator.com/yc-pa…

Post attachment
Nathan C. Frey avatar
⟳ Alec Nielsen retweeted
Nathan C. Frey@nc_frey·Oct 22

Today, we’re announcing an open call for guest investigators in life sciences. Over 8–12 weeks, guest investigators will work directly with my team and other Anthropic researchers to produce analyses and tools for their work. We’ll run our models and harnesses, at no cost to them. We’ll work together to open-source the resulting data, artifacts, and code, and write preprints about what we find. We want humans to remain at the center of scientific discovery, deciding what questions to pursue, and how to pursue them. Those decisions are not ours to make alone. This open call is part of our ongoing efforts at Anthropic to support researchers and accelerate scientific discovery. I’m looking for principal investigators and their research groups at academic institutions, nonprofits, or government labs, working in causal human biology, structural and computational molecular biology, medicinal chemistry, drug discovery, and clinical science. Applications are open for about 14 days: anthropic.com/news/open-call…

Niko McCarty. avatar
⟳ Alec Nielsen retweeted
Niko McCarty.@NikoMcCarty·Oct 15

Our newest book is finally here! Making the Modern Laboratory is a spectacular 504-page hardcover that tells the story of everything in the research laboratory and how it came to be, from pipettes to heat-resistant glass to microscopes and more. It features dozens of articles (most of which will never appear in print), 100+ full-color images, and original writing from 36 authors. It's printed on Arena Natural Rough paper from Fedrigoni. These books are THICC and would make a great gift for both the science-curious and the working scientist. :) We have spent the last year working on this project. It has been an insane labor of love. The best way to support our independent science journalism is to buy a copy. <3 Pre-order for $49, with free shipping: press.asimov.com/articles/mo…

Post attachmentPost attachmentPost attachment
Alec Nielsen avatar
Alec Nielsen@alectricity·Oct 7

Co-sign

In the AI era, I expect to see many new modalities emerge in biotech. These will be therapeutics in unusual shapes and sizes, not the legacy small molecule drugs that our IP laws, tech transfer departments and biopharma term sheets were designed to bring to market. CRISPR was a practice run. It was an experiment to see how well the existing biotech ecosystem is set up to commercialize new modalities. 14 years after the CRISPR patent wars, it should be seen as a failure and motivate significant reform. Imo the failure of CRISPR reveals two needs: 1) We need better legal and financial tools for nonexclusive foundational IP licenses. If a new modality has 100 applications, we can't assign exclusive rights to 3 companies who then spend the next decade suing each other. 2) We need better infrastructure for modality-wide safety trials and re-use of clinical data. If a new modality has 100 applications, we shouldn't demand that each use build a new portfolio of clinical evidence from scratch. I believe the AI era will deliver dozens of CRISPR-scale new medical innovations. Let's not allow the CRISPR fiasco to happen again. statnews.com/2026/10/07/cari…

Jake Wintermute 🧬/acc avatar
⟳ Alec Nielsen retweeted
Jake Wintermute 🧬/acc@SynBio1·Oct 7

In the AI era, I expect to see many new modalities emerge in biotech. These will be therapeutics in unusual shapes and sizes, not the legacy small molecule drugs that our IP laws, tech transfer departments and biopharma term sheets were designed to bring to market. CRISPR was a practice run. It was an experiment to see how well the existing biotech ecosystem is set up to commercialize new modalities. 14 years after the CRISPR patent wars, it should be seen as a failure and motivate significant reform. Imo the failure of CRISPR reveals two needs: 1) We need better legal and financial tools for nonexclusive foundational IP licenses. If a new modality has 100 applications, we can't assign exclusive rights to 3 companies who then spend the next decade suing each other. 2) We need better infrastructure for modality-wide safety trials and re-use of clinical data. If a new modality has 100 applications, we shouldn't demand that each use build a new portfolio of clinical evidence from scratch. I believe the AI era will deliver dozens of CRISPR-scale new medical innovations. Let's not allow the CRISPR fiasco to happen again. statnews.com/2026/10/07/cari…

John Cumbers avatar
⟳ Alec Nielsen retweeted
John Cumbers@johncumbers·Oct 2

Big pharma committed about $6.6 billion to in vivo CAR-T in roughly seven months last year. @abbvie bought @capstantx for $2.1B. @AstraZeneca bought EsoBiotec for up to $1B. @bmsnews paid $1.5B for Orbital. @KitePharma picked up Interius for $350M. EsoBiotec and Interius both run on lentiviral vectors. So does @UmojaBiopharma, which AbbVie partnered with before buying Capstan. Which is why today's news from @AsimovBio and @LonzaGroup caught my attention. In ex vivo cell therapy, the lentivirus is a tool. You use it in a lab to engineer a patient's cells and you're done with it. In vivo flips that. The vector goes into the patient. As @alectricity put it, the vector becomes the drug. That makes manufacturing the hard part. Most lentivirus is still made by transfecting cells with multiple plasmids, batch after batch. It's expensive, variable, and tough to scale. Asimov's LV Edge Producer lines build all the lentiviral genes into the host cell itself. No transient transfection, no GMP plasmid bill, and titers above 1E9 TU/mL for CAR constructs, about 10x what they saw before. Lonza brings the process development, analytics, scale-up and GMP manufacturing. Putting the two together at the cell line stage means manufacturability gets designed in early, before a program hits scale-up and finds out the hard way. If in vivo CAR-T works the way pharma is betting, the bottleneck moves to making enough clean, consistent vector at a cost that works for big indications. That's the problem this collaboration is going after. Alec first spoke at @SynBioBeta in 2018, back when Asimov was a genetic circuits startup. Soren Flygenring Basset from Lonza joined us on stage in San Jose this May. Fun to see these two worlds connect. Congrats to @alectricity, Imroz Ghangas and the @AsimovBio team, and to Daniel Palmacci, Thomas Fellner and Soren at @LonzaGroup.

Post attachment
Alec Nielsen avatar
Alec Nielsen@alectricity·Oct 2

big news for asimov today: we're partnering with lonza on in vivo lentiviral vector manufacturing. i'm pretty excited about this one for a lot of reasons. ex vivo CAR-T has now treated tens of thousands of patients, and many of them have been cured of their cancer. but it requires extracting and engineering human cells outside the body, which means every dose is its own batch. it's an impressive manufacturing effort, but it's hard to scale. in vivo approaches skip the cell extraction step. you dose the gene delivery vector directly into the patient, and it engineers the target cells inside their body. this means one drug product can serve many patients, but the catch is that the vector is now the actual drug, not just a reagent, so consistency and a well-defined product profile matter a lot more. traditionally, lentiviral vectors are made by large-scale transient transfection of a production host cell line, which is plagued by scalability and consistency problems. every cell in the bioreactor can receive a different number of plasmids, anywhere from zero to thousands. stable producer cell lines take a different approach. they're clonal engineered lines with the production genetics integrated into the genome, so no transfection is needed during manufacturing. the whole process starts to look more like antibody manufacturing, which is highly controllable and scalable. (as an aside, refactoring the lentivirus genome to gain tight control over the multi-step molecular process it encodes is one of the most technically impressive feats i've seen since starting asimov) we're seeing order of magnitude higher titers and infectivity with our stable producer systems compared to transient transfection. with lonza, we're pairing that with their process development, analytics, and GMP manufacturing expertise to support drug developers. we think in vivo cell and gene therapies are the future, and that they'll bring many more drugs to patients in the years to come.

Today we are announcing a strategic collaboration with @LonzaGroup to advance in vivo lentiviral vector manufacturing. In vivo lentiviral therapies turn the vector from a manufacturing reagent into the drug itself, raising the bar for titer, product quality, and scale. While traditional transient production systems limit scalability and consistency, stable cell lines have the potential to enable scalable, reproducible and controlled product profiles for lentiviral vectors. To provide developers with a scalable path from sequence to clinic, we’re bringing together Asimov’s LV Edge stable cell lines with Lonza’s expertise in process development, scale-up, analytics and GMP manufacturing. By connecting early design decisions with development and manufacturing considerations, we are creating a stronger foundation for clinical and commercial production. Learn more here: asimov.com/news/lonza-and-as…

Alec Nielsen avatar
Alec Nielsen@alectricity·Sep 22

I love living in the future

Today, Pioneer Labs is announcing our first step towards terraforming Mars. 🚀🌼 With equipment that fits in just a single rocket launch, we can convert Martian dirt, water, and air into enough building materials to construct a small city on Mars. To do it, we made the first microbe for Mars. We found the best microbe on Earth and used evolution to teach it how to source all of its nutrients directly from Martian materials. The first astronauts will be greeted with safe shelter already filled with water, oxygen, and rocket fuel for the return journey. This is the first step toward using biology to make Mars a friendly place for life. It lets us live off the land and helps us build the next great frontier. It's the first of five organisms we need to green Mars ⬇️

1:28
Niko McCarty. avatar
⟳ Alec Nielsen retweeted
Niko McCarty.@NikoMcCarty·Sep 21

When you go skiing in the winter, and see those big machines spitting out snow, know that they are spitting out purified proteins made from dead bacteria. I didn’t realize this until recently! Basically, they take Pseudomonas syringae cells — not engineered; a natural microbe found on plants — and grow them up in huge bioreactors. The cells make ice-nucleating proteins, which sit on their outer membranes and help ice crystals form. The cells are concentrated, freeze-dried, and sterilized until only these proteins remain. The reason these proteins are useful is because they help water molecules form ice more quickly. Water can remain liquid even below 0°C, and only freezes when enough molecules form into a crystal. The proteins have, on their surfaces, repeating snippets of amino acids that help water molecules organize into that shape. So these snow machines just blast super cold water with these proteins, and the two hit the air, mix together, and immediately freeze into snow.

Post attachmentPost attachment
Alec Nielsen avatar
Alec Nielsen@alectricity·Sep 19

v1 gene therapy

But, I'll add: the Romans also made an icosahedron. If it's related, it changes how we should expect to explain the dodecahedron. But no one knows what this one was for either!

Post attachment
Jake Wintermute 🧬/acc avatar
⟳ Alec Nielsen retweeted
Jake Wintermute 🧬/acc@SynBio1·Sep 17

I’ve expected this for a while but it still hurts. The “Life Sciences Verification Program.” It breaks my heart to know that biological knowledge will be locked down and gatekept like this. I want to take a moment to mourn, because I believe this marks an end for open science as I knew it. I think back to my education. I owe so much to the open-access literature. I'm so deeply thankful to the culture of transparency among scientists. All the free knowledge I've been given. The free GenBank sequences. The free PDB structures. The education and know-show that my colleagues shared with me for the pure love of learning. The Life Sciences Verification Program will kill that spirit. The most important biology tools of the next decade will be locked down and controlled. Some fragments of the old literature will remain free, but the real heart of where science happens will not be free. Frontier knowledge will belong only to people who the authorities decide deserve it. I want to fight this, but I don’t think I can. I don’t believe bioterrorism is a serious threat, but convincing people of that is not realistic. The fear is embedded too deep in the psyche. If I tried, there are armies of internet trolls eager to accuse me of evil things. It would become my entire online life. There is a growing and well funded fear-industrial complex dedicated to the idea that Bio-AI is a terrible risk and the people who practice it need to be monitored and policed. Hundreds of full-time professionals whose salary depends on their belief that biology presents a dire threat. What hope do I have of arguing with them? On the other side, the traditional defenders of free information are historically weak. Biology professors are struggling just to keep the lights on. The last thing they want is to be called reckless enemies of national security. They aren’t going to fight this - I’m sure many of them are already signing up to ask for permission to be on the list. So I’m writing this to bear witness. This is how it ended. Biology isn’t going to be free going forward. That was an idea of the pre-AI era and it is over now. The fight now isn’t over free access to information. It’s over who gets verified access to the closed information. Big pharma companies get permission, of course. So do professors at elite universities. But we can petition Anthropic to expand that list. Maybe they might allow access for high school teachers, medical students and nurses? I hope they will approve farmers, iGEM teams, community biolabs, birdwatchers, park rangers and community gardens. Will Anthropic allow those people to study biology at the frontier? As of today, the power officially belongs to them. We can only ask.

Today we’re opening applications for the Life Sciences Verification Program. Through the LSVP, life science professionals can use our models—including, for the first time, Mythos—with a new set of safeguards designed to enable the full range of biology-related work. We designed these new safeguards to provide a better experience for biologists and more protection from risk of misuse. The program is launching in beta for teams of all kinds—from academic labs to startups, pharma companies, and more. We will continue to improve the program and expand access to individual Pro and Max plans over time. Learn more about these access grants and apply: anthropic.com/news/life-scie…

Sri Kosuri avatar
⟳ Alec Nielsen retweeted
Sri Kosuri@srikosuri·Sep 15

Today, there's a strong focus on fast-follows of existing drugs. The drug programs that inspire me look different – the target is known, but we don't know how to build the drug, often requiring the dev of new tech that paves the path for more drugs.